KNSA - CIK 0001730430
Kiniksa Pharmaceuticals, Ltd. (KNSA) reported net income of $59.01M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $59.01M | +236.6% |
| FY 2024 | -$43.19M | -406.7% |
| FY 2023 | $14.08M | -92.3% |
| FY 2022 | $183.36M | +216.1% |
| FY 2021 | -$157.92M | +2.1% |
| FY 2020 | -$161.38M | +0.3% |
| FY 2019 | -$161.87M | -56.8% |
| FY 2018 | -$103.23M | -59.1% |
| FY 2017 |
Kiniksa Pharmaceuticals, Ltd. (KNSA) reported net income of $59.01M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, Kiniksa Pharmaceuticals, Ltd.'s net income grew from -$64.87M to $59.01M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$64.87M |
| - |